Extended release amphetamine compositions

An orally administrable extended release amphetamine liquid suspension comprising:

• (A) at least one modified release component comprising an amphetamine-cation exchange resin complex-optional matrix, wherein the amphetamine-cation exchange resin complex comprises (i) two or more amphetamines both bound to the same cation exchange resin, wherein when the optional matrix is present, the amphetamine-cation exchange resin complex-matrix further comprises a hydrophilic polymer or copolymer or a hydrophobic polymer and (ii) a water-insoluble, water-permeable, pH-independent, barrier coating which provides a sustained or extended release to the two or more amphetamines, wherein the two or more amphetamines of (i) are at least a d-amphetamine and an l-amphetamine, wherein the d-amphetamine and the l-amphetamine are provided by d-amphetamine and at least one of (d,l)-amphetamine and l-amphetamine;
• (B) a first immediate release amphetamine component which comprises d-amphetamine or a pharmaceutically acceptable salt thereof, and l-amphetamine or a pharmaceutically acceptable salt thereof, or mixtures thereof, wherein the d- and l-amphetamine are provided by d-amphetamine and at least one of (d, l)-amphetamine and l-amphetamine;
• and
• (C) a second immediate release amphetamine component which comprises an amphetamine-cation exchange resin complex in an optional matrix, wherein the amphetamine-cation exchange resin complex-optional matrix comprises at least a d-amphetamine and an l-amphetamine both bound to the same cation exchange resin, wherein the d-amphetamine and the l-amphetamine are provided by d-amphetamine and at least one of (d, l)-amphetamine or l-amphetamine;
• wherein none of the amphetamine components in the suspension has a delay release coating which delays the release of the amphetamines,
• wherein based on the weight of the total amphetamines as calculated on the basis of the free base amphetamines, the modified release component (A) comprises 45% to 75% by weight of the total amphetamines in the suspension, the immediate release component (B) comprises 5% to 25% by weight of the total amphetamines in the suspension, and immediate release (C) comprises 30% to 40% by weight of the total amphetamines in the suspension;
• and
• wherein the suspension provides at least one immediate release profile for d-amphetamine and for l-amphetamine and a therapeutic profile for at least 13 hours for d-amphetamine and for l-amphetamine;
• wherein the suspension comprises a ratio of about 3 parts by weight d-A amphetamine to about 1 part by weight l-amphetamine.